These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33347636)

  • 41. Patterns in Outpatient Benzodiazepine Prescribing in the United States.
    Agarwal SD; Landon BE
    JAMA Netw Open; 2019 Jan; 2(1):e187399. PubMed ID: 30681713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
    [No Abstract]   [Full Text] [Related]  

  • 43. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benzodiazepine prescribing guideline adherence and misuse potential in Irish minors.
    Murphy KD; Sahm LJ; McCarthy S; Byrne S
    Int J Clin Pharm; 2015 Oct; 37(5):749-52. PubMed ID: 26040836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An empirical review of the impact of triplicate prescription of benzodiazepines.
    Schwartz HI
    Hosp Community Psychiatry; 1992 Apr; 43(4):382-5. PubMed ID: 1349557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Examination of Concurrent Opioid and Benzodiazepine Prescribing in 9 States, 2015.
    Guy GP; Zhang K; Halpin J; Sargent W
    Am J Prev Med; 2019 Nov; 57(5):629-636. PubMed ID: 31564606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.
    Sidorchuk A; Isomura K; Molero Y; Hellner C; Lichtenstein P; Chang Z; Franck J; Fernández de la Cruz L; Mataix-Cols D
    PLoS Med; 2018 Aug; 15(8):e1002635. PubMed ID: 30086134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 49. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of FDA safety warnings may vary.
    Kuehn BM
    JAMA; 2012 Mar; 307(9):894-5. PubMed ID: 22396504
    [No Abstract]   [Full Text] [Related]  

  • 51. Black-Box Warnings of Antiseizure Medications: What is Inside the Box?
    Wahab A; Iqbal A
    Pharmaceut Med; 2023 May; 37(3):233-250. PubMed ID: 37119452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
    Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012].
    Hoffmann F; Glaeske G
    Nervenarzt; 2014 Nov; 85(11):1402-9. PubMed ID: 24663439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
    Rose RV; Kass JS
    Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measuring the Effectiveness of Benzodiazepine Prescriptions Control in Community Setting Using Prescription Drug Monitoring Program (PDMP).
    Agrawal R; Verma S; Halappanavar M
    Community Ment Health J; 2021 Jul; 57(5):920-925. PubMed ID: 32666418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
    Kohan LR; Elmofty D; Pena I; Liao C
    J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning.
    Cook BL; Wang Y; Sonik R; Busch S; Carson N; Progovac AM; Zaslavsky AM
    Health Serv Res; 2019 Feb; 54 Suppl 1(Suppl 1):255-262. PubMed ID: 30666633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FDA safety warnings and trends in testosterone marketing to physicians.
    Togun A; Sankar A; Karaca-Mandic P
    Am J Manag Care; 2022 Mar; 28(3):e78-e79. PubMed ID: 35404550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentially inappropriate benzodiazepine use in Australian adults: A population-based study (2014-2017).
    Zheng D; Brett J; Daniels B; Buckley NA; Pearson SA; Schaffer AL
    Drug Alcohol Rev; 2020 Jul; 39(5):575-582. PubMed ID: 32391624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.